Recently, Alpert et al. [25] found that TP53 mutations are common in inflammatory bowel disease-associated colon cancer, while the frequency of APC and KRAS mutations was significantly lower than in sporadic CRC (Table 1) [25,26]. Here, KRAS is linked to malignant colon neoplasm.